Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.

Although liver resection is the best treatment for colorectal liver metastases (CLM), only 20% of cases are initially resectable, while others require conversion chemotherapy (CTx) before undergoing secondary resection after downsizing.1 Some patients, however, have definitively unresectable CLM for

Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).1,2 Results from the phase 3 FLAURA trial showed that os

The phase 2 FLAURA2 study found that first-line combination of osimertinib and chemotherapy (CT) offered significant survival benefits among patients who were diagnosed with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) compared to first-l

Results from the phase 3 CheckMate 816 study had found that neoadjuvant nivolumab plus chemotherapy (CTx) induced clinically significant and sustained benefits in the event-free survival (EFS) and overall survival (OS) of patients with resectable non-small cell lung cancer (NSCLC) comp

While platinum-based chemotherapy (CTx) has been the standard first-line (1L) treatment for locally advanced metastatic urothelial carcinoma (la/mUC) for decades, many patients continue to experience disease progression after treatment, resulting in poor prognosis and low 5-year surviv

Immune checkpoint inhibitor (ICI)-based treatments are one of the front-line options for patients with advanced non-small cell lung cancer (NSCLC).¹ However, no optimal duration has been defined.¹ At the ASCO 2023 Annual Meeting, Dr. Lova Sun from the University of Pennsylvania, the United States (US), presented the results of a US study that investigated the clinical practice patterns surrounding ICI treatment discontinuation at 2 years.¹ Furthermore, the association between the duration of therapy with overall survival (OS) was evaluated by comparing patients who received ICIs for 2 years with those who had received ICIs beyond 2 years.¹

Non-small cell lung cancer (NSCLC) accounts for 85%of all types of lung cancer and is the most common cancer in Hong Kong with a total of 5,575 cases in 2019.^1,2 Approximately 30% of NSCLC patients are diagnosed as early stage, and surgical resection is the preferred treatment option for possibly co

A retrospective study on a pediatric population has shown that neurologic manifestations (NMs) in patients with acute leukemia (AL), relating to a greater mortality rate.1 AL is the most prevalent childhood cancer, which accounts for one-third of all cancers within the age range.1 Although the survi